课题基金 / 基金详情

Patient derived organoids as a platform for inferring treatment response in pancreatic cancer patients

Patient derived organoids as a platform for inferring treatment response in pancreatic cancer patients
源自患者的类器官作为推断胰腺癌患者治疗反应的平台
批准号：
451144
负责人：
Gallinger Steven
金额：
$71.06万
依托单位：
Ontario Institute for Cancer Research (Toronto, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-09-01 至 2026-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=451144&lang=en
关键词：
Better Treatment Selection For Patients Chemosensitivity And Resistance Genomic And Transcriptomic Sequencing Improving Survival And Patient Outcome Models Of Patient Response Pancreatic Cancer Patient Derived Organoids Pharmacotyping Targeted Can

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Pancreatic cancer is one of the deadliest cancers. Most patients are diagnosed when the tumour is too big or has spread to other organs, so it can no longer be removed by surgery. The only alternative is to treat the tumour with chemotherapy. To date, the
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金